Source 1primary paper2026MED
Toolkit/BMV virus-like particles
BMV virus-like particles
Also known as: BMV-VLPs, Brome Mosaic Virus-like particles, plant-derived BMV-VLPs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
plant virus-like particles (VLPs), derived from Brome Mosaic Virus (BMV), as a biodegradable and biocompatible nanocarrier for small interfering RNA (siRNA) delivery aimed at modulating immune checkpoints in melanoma
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Develop and validate BMV-derived virus-like particles as a biodegradable and biocompatible siRNA delivery platform for PD-L1 checkpoint modulation and immunomodulation in melanoma-related in vitro systems.
Why it works: The workflow couples a modular VLP assembly platform with cell-based uptake, knockdown, and immune-function assays so that physical carrier properties and downstream biological activity can be evaluated in sequence.
in vitro self-assembly of recombinant BMV capsid proteins into siRNA-loaded VLPsRNA interference-mediated PD-L1 silencingcheckpoint modulation to alter T-cell responsesrecombinant protein expression in E. coliin vitro VLP self-assemblyconfocal microscopyflow cytometrycell-based knockdown assaysmixed leukocyte reaction
Stages
- 1.BMV capsid expression and VLP assembly(library_build)
This stage creates the siRNA-loaded BMV-VLP formulation needed for all downstream characterization and cell-based testing.
Selection: Generate uniform BMV-derived VLPs encapsulating PD-L1 siRNA.
- 2.Physicochemical and compatibility characterization(functional_characterization)
This stage checks whether the assembled particles are suitable for biological testing and not overtly toxic.
Selection: Assess whether the VLPs have high structural stability, efficient siRNA encapsulation, and biocompatibility.
- 3.Cellular uptake assessment(secondary_characterization)
Uptake confirmation provides evidence that the carrier can enter cells before interpreting knockdown and immune-function outcomes.
Selection: Confirm that BMV-VLPs are taken up by cells.
- 4.Functional knockdown testing(confirmatory_validation)
This stage verifies that uptake leads to biologically active siRNA delivery rather than passive particle internalization alone.
Selection: Demonstrate functional siRNA delivery by target knockdown in relevant cell models.
- 5.Immunomodulatory functional validation(confirmatory_validation)
This stage links molecular PD-L1 knockdown to downstream immune consequences relevant to checkpoint modulation.
Selection: Test whether PD-L1 silencing translates into immune-functional effects.
Steps
- 1.Express recombinant BMV capsid proteins in E. coli
Produce the capsid protein building blocks required for VLP formation.
Capsid proteins must be generated before in vitro assembly of siRNA-loaded particles can occur.
- 2.Self-assemble siRNA-loaded BMV-VLPs in vitroengineered delivery vehicle
Generate uniform VLPs encapsulating PD-L1-directed siRNA for downstream testing.
Assembly follows capsid production because the delivery vehicle must be formed before characterization and cell-based validation.
- 3.Characterize stability, encapsulation, and biocompatibilityformulated nanocarrier under evaluation
Establish that the assembled VLPs are stable, loaded, and biocompatible enough for cell-based testing.
These checks reduce the risk of misinterpreting downstream biological results caused by unstable or toxic particles.
- 4.Measure cellular uptake by confocal microscopy and flow cytometrydelivered nanocarrier
Confirm that the VLPs enter cells efficiently.
Uptake is assessed before functional knockdown so that later gene-silencing results can be interpreted in light of delivery into cells.
- 5.Test functional siRNA delivery by target knockdown in cell modelssiRNA delivery vehicle
Demonstrate that internalized VLPs deliver biologically active siRNA capable of silencing target genes.
This follows uptake confirmation because gene knockdown is a higher-fidelity readout of productive intracellular delivery than uptake alone.
- 6.Assess downstream immune-functional consequences of PD-L1 silencingcheckpoint-silencing delivery vehicle
Determine whether molecular PD-L1 knockdown translates into immunomodulatory effects relevant to melanoma immunotherapy.
This is performed after knockdown is shown because immune-functional changes are intended as downstream consequences of successful checkpoint silencing.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
cellular uptakerna interference-mediated gene silencingsirna encapsulationvirus-like particle self-assemblyTarget processes
recombinationInput: Chemical
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Recombinant BMV capsid proteins expressed in E. coli self-assembled in vitro into uniform VLPs encapsulating PD-L1-directed siRNA.
Recombinant BMV capsid proteins were expressed in E. coli and self-assembled in vitro into uniform VLPs encapsulating siRNA directed against the programmed death-ligand 1 (PD-L1).
BMV-VLPs showed high cellular uptake in vitro as assessed by confocal microscopy and flow cytometry.
In vitro, A high cellular uptake was confirmed by confocal microscopy and flow cytometry.
BMV-VLPs mediated functional siRNA delivery in vitro, producing eGFP knockdown in macrophages and PD-L1 knockdown in B16F10 melanoma and JAWS II dendritic cells.
functional siRNA delivery was demonstrated in vitro by knockdown of eGFP in macrophages and PD-L1 in B16F10 melanoma and JAWS II dendritic cells, with significant knockdown efficiencies comparable to controls
knockdown efficiency significant and comparable to controls
PD-L1 silencing mediated by BMV-VLPs increased CD8+ T-cell-mediated cytotoxicity in melanoma and CMT64 tumor models and enhanced allogeneic T-cell proliferation in dendritic cell-based mixed leukocyte reactions.
PD-L1 silencing mediated by BMV-VLPs induced functional immunomodulation, increasing CD8⁺ T-cell-mediated cytotoxicity in melanoma and CMT64 tumor models and enhancing allogeneic T-cell proliferation in dendritic cell-based mixed leukocyte reactions.
The BMV-VLPs showed high structural stability, efficient siRNA encapsulation, and excellent biocompatibility.
The VLPs displayed high structural stability, efficient siRNA encapsulation, and excellent biocompatibility.
BMV-VLPs could complement antibody-based PD-1/PD-L1 blockade strategies and represent a sustainable and versatile alternative to synthetic lipid systems for RNA immunotherapy.
these findings indicate that plant-derived BMV-VLPs can safely mediate RNA-based checkpoint modulation and could complement antibody-based PD-1/PD-L1 blockade strategies. Owing to their intrinsic biocompatibility, scalability, and modular design, BMV-VLPs represent a sustainable and versatile alternative to synthetic lipid systems for RNA immunotherapy.
BMV virus-like particles can be used as a biodegradable and biocompatible nanocarrier for siRNA delivery aimed at immune checkpoint modulation in melanoma.
we evaluated the potential of plant virus-like particles (VLPs), derived from Brome Mosaic Virus (BMV), as a biodegradable and biocompatible nanocarrier for small interfering RNA (siRNA) delivery aimed at modulating immune checkpoints in melanoma
Approval Evidence
1 source7 linked approval claimsfirst-pass slug bmv-virus-like-particles
plant virus-like particles (VLPs), derived from Brome Mosaic Virus (BMV), as a biodegradable and biocompatible nanocarrier for small interfering RNA (siRNA) delivery aimed at modulating immune checkpoints in melanoma
Source:
assembly and formulationsupports
Recombinant BMV capsid proteins expressed in E. coli self-assembled in vitro into uniform VLPs encapsulating PD-L1-directed siRNA.
Recombinant BMV capsid proteins were expressed in E. coli and self-assembled in vitro into uniform VLPs encapsulating siRNA directed against the programmed death-ligand 1 (PD-L1).
Source:
cellular uptakesupports
BMV-VLPs showed high cellular uptake in vitro as assessed by confocal microscopy and flow cytometry.
In vitro, A high cellular uptake was confirmed by confocal microscopy and flow cytometry.
Source:
functional deliverysupports
BMV-VLPs mediated functional siRNA delivery in vitro, producing eGFP knockdown in macrophages and PD-L1 knockdown in B16F10 melanoma and JAWS II dendritic cells.
functional siRNA delivery was demonstrated in vitro by knockdown of eGFP in macrophages and PD-L1 in B16F10 melanoma and JAWS II dendritic cells, with significant knockdown efficiencies comparable to controls
Source:
functional immunomodulationsupports
PD-L1 silencing mediated by BMV-VLPs increased CD8+ T-cell-mediated cytotoxicity in melanoma and CMT64 tumor models and enhanced allogeneic T-cell proliferation in dendritic cell-based mixed leukocyte reactions.
PD-L1 silencing mediated by BMV-VLPs induced functional immunomodulation, increasing CD8⁺ T-cell-mediated cytotoxicity in melanoma and CMT64 tumor models and enhancing allogeneic T-cell proliferation in dendritic cell-based mixed leukocyte reactions.
Source:
performance propertysupports
The BMV-VLPs showed high structural stability, efficient siRNA encapsulation, and excellent biocompatibility.
The VLPs displayed high structural stability, efficient siRNA encapsulation, and excellent biocompatibility.
Source:
positioningsupports
BMV-VLPs could complement antibody-based PD-1/PD-L1 blockade strategies and represent a sustainable and versatile alternative to synthetic lipid systems for RNA immunotherapy.
these findings indicate that plant-derived BMV-VLPs can safely mediate RNA-based checkpoint modulation and could complement antibody-based PD-1/PD-L1 blockade strategies. Owing to their intrinsic biocompatibility, scalability, and modular design, BMV-VLPs represent a sustainable and versatile alternative to synthetic lipid systems for RNA immunotherapy.
Source:
tool capabilitysupports
BMV virus-like particles can be used as a biodegradable and biocompatible nanocarrier for siRNA delivery aimed at immune checkpoint modulation in melanoma.
we evaluated the potential of plant virus-like particles (VLPs), derived from Brome Mosaic Virus (BMV), as a biodegradable and biocompatible nanocarrier for small interfering RNA (siRNA) delivery aimed at modulating immune checkpoints in melanoma
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.